Abstract 3864
Background
Role of Tg levels as a biomarker in RAI-R DTC during MKI is unclear. Falling levels of Tg after starting MKI treatment has been previously reported, with a higher reduction in patients who achieve response. However, transient Tg oscillations are a common phenomenon during therapy without a clear correlation with progressive disease (PD). In the present study, we analyze the correlation between Tg oscillations and progression-free survival (PFS) in patients with RAI-R DTC during MKI treatment.
Methods
Thirty-seven consecutive patients were reviewed. Inclusion criteria were: pathology confirmed RAI-R DTC, age >18 years, MKI treatment in the first or second line and serial Tg determinations along with the follow-up. Variations in Tg levels during MKI treatment were evaluated. As exploratory hypothesis, we considered the “Tg elevation non-PD related”, defined as a significant elevation of Tg higher than 50% compared with previous measure, not related with PD by RECIST criteria, followed by a Tg reduction in a subsequent determination, in patients with an initial Tg reduction after starting MKI treatment.
Results
33 patients were included in the final analysis. Most MKI treatments were Sorafenib (44%), Lenvatinib (27%), Vandetanib (10%) and Axitinib (8%). Median duration of treatment was 15.5 months, and median PFS 20.2 months. Patients with any Tg levels reduction compared with baseline along MKI treatment showed a better PFS (23.5 vs. 3.6 months, p < 0.001). A Tg reduction >50% from baseline on the first month after starting MKI also had a benefit in PFS (27.7 vs. 14.2, p 0.02). 20.6% of cases had the nadir of Tg response beyond the first month of treatment. 34.4% of cases presented Tg elevation non-PD related along with follow-up (median number of elevations per patient: 2), with a better PFS compared with patients with other Tg oscillation patterns (29.9 vs. 15.5 months, p0.008).
Conclusions
Tg elevation non-PD related was associated with a better PFS compared with patients with other Tg variation patterns. Treatment with MKIs should not be stopped or changed based on Tg variations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Hernando Cubero: Speaker Bureau / Expert testimony: Eisai, Ipsen, Roche, Angelini Pharma; Travel / Accommodation / Expenses: Ipsen, Novartis, AAA, Roche, AstraZeneca, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
4390 - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
Presenter: Sakti Chakrabarti
Session: Poster Display session 2
Resources:
Abstract
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract